Takeda overhauls R&D, focusing on Boston and Japan in global reorganization
New Takeda CEO Christophe Weber is pushing plans for a global R&D overhaul, concentrating efforts in Japan and the U.S. as the Japanese pharma company pursues three key therapeutic arenas and amps up efforts to forge more research collaborations.
Takeda’s UK operations are coming under the ax in the revamp, with the company beginning the first “consultation” stage of the layoff process. The UK hosts a preclinical R&D operation in Cambridge as well as a development center HQ with facilities in the UK, Switzerland and Denmark.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.